However, a short-term triple therapy regimen consisting of RAPA, agonist IL-2-related as well as antagonist IL-15-related Ig fusion proteins was shown to be suitable to effectively cure overt new-onset T1D in NOD mice [77]. The gene discussed is IL2; the disease is type 1 diabetes mellitus.